Stem cells isolated from the amniotic fluid have been shown as a promising candidate for cell therapy and tissue engineering. However, the experimental and preclinical applications of amniotic fluid-derived stem cells (AFSCs) in the very field of maxillofacial bone tissue engineering are still limited. In this study, rat AFSCs were successfully harvested and characterized in vitro. The rat AFSCs showed typical fibroblastoid morphology, stable proliferation activity and multidifferentiation potential. Flow-cytometry analysis demonstrated that these cells were positive for CD29, CD44, and CD90, while negative for hematopoietic markers such as CD34 and CD45. The regenerative performance of AFSCs-premixed with platelet rich plasma (PRP) gel in restoration of alveolar bone defect was further investigated using a modified rat maxillary alveolar defect model. Micro-computer tomography and histological examination showed a superior regenerative capacity of AFSCs-premixed with PRP gel at both 4 and 8 weeks after operation comparing with control groups. Moreover, the implanted AFSCs can survive in the defect site and directly participate in the bone tissue regeneration. Taken together, these results indicated the feasibility of an AFSCs-based alveolar bone tissue engineering strategy for alveolar defect restoration.
Introduction
Alveolar cleft, featured as congenital alveolar bone defects and developmental maxillofacial anomalies, is the result of abnormal primary palate formation during weeks 4-12 of gestation, which often leads to dental arch disruption, teeth mal-eruption, and facial disfigurement [1] . Currently, the most widely accepted treatment methods for alveolar cleft is the secondary autogenous bone grafting in the mixed dentition [2] . However, donor site defects, potential infection, operative trauma, and even morbidity are among the limitations of autogenous bone grafting. In addition, reconstruction of alveolar cleft in the pediatric population may also be hindered by inadequate bone graft donor volume, which leads to the delay of restoration until a certain age and deterioration of the deformity with physical growth.
In 2006, Hibi et al. [3] reported that the successful application of autologous bone marrow mesenchymal stem cells (BMSCs) mixed with platelet rich plasma (PRP) for alveolar cleft osteoplasty of a 9-year-old female patient, providing the first evidence that stem cells can be clinically used to restore congenital alveolar bone defect. Likewise, Behnia et al. [4, 5] reported the successful treatment of several alveolar cleft patients using BMSCs and different biomaterials. The postoperative radiography of these studies demonstrated clear evidence of osseous union across the cleft and no tumor formation was noted. More recently, two independent groups of researchers described the utilization of autologous BMSCs to reconstruct alveolar bone defects in adult patients with favorable results [6, 7] . Based on recent clinical and experimental studies, stem cell-based bone tissue engineering has been recognized as a promising strategy for restoration of alveolar bone defects. However, the drawbacks of BMSCs such as invasive cell collection, surgical trauma, potential donor site infection, and limited cell quantity significantly restrict their use in pediatric patients.
In 2007, De Coppi et al. [8] reported the successful isolation of a multipotential population of stem cells in the amniotic fluid. These amniotic fluid-derived stem cells (AFSCs) can be readily isolated from a 1 to 2 ml amniotic fluid specimen during amniocentesis or cesarean delivery and cryopreserved in vitro. When cultured under controlled conditions, AFSCs showed enhanced multi-differentiation capabilities into cells and tissues from all three embryonic germ layers, confirmed by several independent reports [8] [9] [10] [11] [12] [13] [14] [15] . Moreover, AFSCs have been shown to be non-tumorigenic and provide a fetusorigin immunological homology, supporting their safety in autogenous application [16] [17] [18] [19] . All these attractive features make AFSCs a logical and promising cell source for autologous stem cell-based tissue engineering in restoration of pediatric congenital defects.
In this study, an AFSCs-based bone tissue engineering strategy for congenital alveolar cleft restoration was proposed (Fig. 1) , and the regenerative properties of AFSCs in restoration of alveolar bone defect were evaluated using a modified Sprague-Dawley (SD) rat model. Our data indicated the proper bone regenerative performance of AFSCs and primary feasibility of an AFSCs-premixed PRP gel (AFSCs-PRPG) in the restoration of alveolar defect.
Materials and Methods

Experimental animal
Male SD rats were obtained from animal experiment center of Shanghai Ninth People's Hospital (Shanghai, China). Rat care and handling in this study was conformed to the National Institutes of Health recommended guidelines for animal research. All experimental protocols were approved by the Animal Research Ethics Committee of Shanghai Ninth People's Hospital.
AFSCs isolation and culture
The rat AFSCs were isolated and expanded as previously described [12, 20, 21] . Briefly, 0.8-1.0 ml amniotic fluid samples were carefully drained from the amniotic sac of pregnant SD rats at gestational age 15 ± 2 days. All samples were centrifuged for 10 min at 600 g and cell pellets were resuspended in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, USA) supplemented with 20% fetal bovine serum (Gibco, Gaithersburg, USA), 1% penicillin-streptomycin (Gibco), 10 ng/ml bFGF (Invitrogen), and cultured in a six-well plate at 37°C with 5% CO 2 and 100% humidity. After 5 days, the culture medium was changed and adherent cells were observed at the bottom of the plate. When the culture reached~80% confluency, the AFSCs were routinely passaged. The expansion culture medium was changed every 3 days.
Assessment of AFSC proliferation in vitro
AFSCs at Passages 1, 3, and 5 (P1, P3, and P5) were seeded at 2 × 10 3 cells/ well into a 96-well plate and cultured for 4 h (represented as Day 0), 2, 4, and 6 days, respectively. At each time point, a Cell Counting Kit-8 (CCK-8; Dojindo, Tokyo, Japan) was used to assess the cell proliferation activity according to the manufacturer's instructions in triplicate.
Flow-cytometry analysis
For flow-cytometry analysis, P3 AFSCs were incubated and examined with phycoerythrin upregulate (PE)-conjugated anti-rat CD34 (Santa Cruz Biotech, Santa Cruz, USA), PE-conjugated anti-rat CD29 (Biolegend, San Diego, USA), PE-conjugated anti-rat CD45 (Biolegend), fluorescein isothiocyanate (FITC)-conjugated anti-rat CD44 (Serotec, Oxford, UK), FITC-conjugated anti-rat CD90 (Serotec) antibodies as previously described [22] . Nonspecific fluorescence was determined by using isotype-matched monoclonal antibody controls.
In vitro multi-differentiation assay
To demonstrate the multipotency of AFSCs, P3 AFSCs at 70%-80% confluency underwent in vitro osteogenic, chondrogenic, and adipogenic induction. For osteogenic differentiation, AFSCs were cultured with either osteogenic or expansion culture medium up to 21 days in 12-well plates as previously described [22] . After osteogenic differentiation for 7, 14, and 21 days, alkaline phosphatase (ALP) staining and alizarin-red staining were performed to visualize the cellular ALP activity and extracellular calcium deposition. For chondrogenic differentiation, AFSCs were cultured with either chondrogenic or expansion culture medium up to 14 days in 24-well plates as previously described [23] . Since Collagen II is one of the major structural components of cartilage and is widely accepted as one of the markers for chondrogenic differentiation, cytoimmunofluorescence staining for Type II collagen was performed with primary rabbit polyclonal anti-Collagen II antibodies (Abcam, Cambridge, UK) using the method as previously described [22] [23] [24] . For adipogenic differentiation, AFSCs were cultured under either adipogenic or expansion culture medium for 14 days in a 24-well plate as previously described [25] . After adipogenic induction, OilRed-O staining was performed to visualize the presence of lipids.
To further verify the multi-differentiation of AFSCs, real-time polymerase chain reaction (PCR) was also performed. Briefly, P3 AFSCs were cultured under either osteogenic, condrogenic, adipogenic, or expansion culture medium up to 14 days in six-well plates. At 0, 7, and 14 days after induction, total ribonucleicacid of each group was extracted and reverse-transcribed into complementary DNA using a reverse transcriptase-polymerase chain reaction kit (TaKaRa, Dalian, China). The cycle threshold (CT) value of Runx2, Collagen Type I, α1 (ColI-a1), Osteocalcin (Ocn), Collagen Type II, α1 (ColII-a1), Sox9, Ppar-γ, and housekeeping gene GAPDH were determined using SYBR Premix PCR kit (TaKaRa) on the real-time PCR machine (ABI 7300, ABI, Foster City, USA). Primers were shown in Supplementary Table S1 . Data were analyzed using a comparative CT method and expressed as fold change.
Gel preparation and alveolar defect restoration
The insoluble gels for alveolar bone defect restoration were prepared using constitutions of AFSCs, PRP, fibrinogen, and thrombin. Briefly, the fibrinogen solution (FS, 100 mg/ml) was prepared using a bovine fibrinogen kit (Jingke Corp., Beijing, China). The PRP was collected from peripheral blood of one donor SD rat and prepared using a two-stage centrifuging method as previously described [26] [27] [28] . Four samples of P3 AFSCs labeled with lenti-GFP from separate donors were collected and resuspended in the FS at a density of 1 × 10 7 cells/ml (AFSCs-premixed FS), respectively. The thrombin solution (TS, 5 U/ml) was prepared by dissolving bovine thrombin (Sigma, St Louis, USA) in 10% calcium chloride solutions. After FS was diluted to the appropriate concentrations by adding PRP or PBS, the gel clotting reaction was activated by mixing TS into FS and group settings were listed as below: Group 1, AFSCs-premixed FS + PRP + TS (1:1:2 ratio); Group 2, AFSCs-premixed FS + PBS + TS (1:1:2 ratio); and Group 3, FS + PBS + TS (at 1:1:2 ratio). Rat maxillary alveolar bone defect was created according to the previously reported methods [29] [30] [31] . Briefly, 24 4-week-old SD rats were randomly divided into 3 groups. Anesthesia was performed with an intraperitoneal injection of 5% ketamine hydrochloride (0.3 ml/100 g body weight). A 1-1.5 cm longitudinal incision was made in the gingiva of left maxilla and the left first molar was extracted. A standardized alveolar defect (4 mm anteroposterior, 3 mm mediolateral, and 3 mm deep) was created using a handoperated, low-speed dental bur (Dremel, Racine, USA) under constant saline irrigation. The prepared three groups of gel were immediately transplanted into the defects. After surgery, animals were fed with a soft diet for the first 3 days post-operatively and advanced to the standard diet. At 4 and 8 weeks after surgical operation, animals were killed under deep anesthesia and maxilla samples were collected, respectively (4 rats in each group at each time point).
Micro-CT and histological analysis
Samples from each group were fixed and imaged using a micro-CT (Skyscan, Kontich, Belgium) with a resolution of 20 mm. Region of interest for bone tissue analysis was taken through the entire length of the defect. After micro-CT scan, samples were decalcified and paraffin embedded. For morphological study, 5-mm coronal sections were stained with hematoxylin and eosin (HE) and photographed.
A histomorphometric quantification of new bone formation within the defect was conducted using software Photoshop CS5 (Adobe Systems Inc., San Jose, USA) as previously described [32] [33] [34] [35] .
Immunohistological analysis
For immunohistochemistry analysis, 5-mm coronal sections were deparaffinized and incubated in citrate buffer at 90°C for 30 min to retrieve antigen and cooled at room temperature (RT). All samples were rinsed with PBS, blocked with 5% bovine serum albumin for 60 min and treated with 3% H 2 O 2 for 10 min. Then, the sections were incubated with primary rabbit polyclonal anti-rat Ocn antibodies (1:100; Santa Cruz Biotech) at 4°C overnight, and visualized using a ABC (Vector Laboratories, Burlingame, USA) method. Selective semi-quantification of immunohistochemistry was performed using the Photoshop CS5 software as previously described [32] [33] [34] [35] .
To further confirm the existence of AFSCs, selective samples were prepared and underwent histoimmunofluorescence assay. Briefly, sections incubated with primary rabbit polyclonal anti-rat Ocn antibodies were incubated with Cy3-labeled goat anti-rabbit IgG in a dark humidified chamber for 1 h at RT. At the end of the incubation, sections were counterstained with DAPI (1:5000; Beyotime, Haimen, China) and photographed under a fluorescence microscope (DP72; Olympus, Tokyo, Japan). 
Statistical analysis
All data were expressed as the mean ± standard deviation and selective measurements were analyzed using two-way ANOVA test. A P value < 0.05 was considered as statistically significant. 
Results
Isolation of AFSCs
After 10-14 days of primary culture and normal passaging, adherent spindle-like rat AFSCs were successfully isolated and passaged ( Fig. 2A) . The proliferation of P1, P3, and P5 AFSCs was significantly increased with time, while no significant difference of proliferation was observed among three passages (Fig. 2B) . Flow-cytometry analysis revealed that P3 AFSCs positively expressed CD29, CD44, and CD90, but did not express CD34 or CD45 (Fig. 2C) .
In vitro osteogenic, chondrogenic, and adipogenic differentiation of AFSCs
After in vitro osteogenic induction, ALP staining confirmed the progressively increased cellular ALP activities of AFSCs in the osteogenic groups whereas low cellular ALP activities were observed in the control group (Fig. 3A) . Alizarin-red staining further showed the progressively increased extracellular mineralization after osteogenic differentiation of AFSCs (Fig. 3A) . AFSCs cultured with either chondrogenic or expansion culture medium for 14 days were immunofluorescence-stained for Col-II and counterstained with DAPI. After chondrogenic induction, Col-II was strongly visible as the red fluorescence, while not detectable in the control group Figure 4 . Real-time PCR analysis of AFSCs at days 7 and 14 after osteogeni, chondrogenic, and adipogenic induction The expressions of Runx2, ColIa1, Ocn in osteogenic group, Sox9, ColIIa1 in chondrogenic group, and Ppar-γ in adipogenic group were significantly up-regulated compared with those in the control group (P < 0.05). PCR, polymerase chain reaction. (Fig. 3B) . Oil-Red-O staining showed the presence of lipids in AFSCs after the adipogenic induction whereas no lipids were observed in the control group (Fig. 3C) .
To further confirm the specific gene expressions for osteogenic, chondrogenic, and adipogenic differentiation, real-time PCR was also performed. At Days 7 and 14 after induction, the expressions of Runx2, ColIa1, and Ocn in osteogenic group, the expressions of Sox9 and ColIIa1 in chondrogenic group, as well as the expression of Ppar-γ in adipogenic group, were all significantly up-regulated compared with those in the control group (P < 0.05) (Fig. 4) .
AFSCs-premixed PRPG significantly promoted the restoration of alveolar defect
Surgical procedure was successfully performed on all animals. A clear sign of progressive alveolar bone restoration was observed in all groups through micro-CT examination (Fig. 5) and HE staining (Fig. 6) . Notably, Micro-CT imaging revealed a significantly higher amount of bone-volume-to-tissue-volume ratio (BV/TV) in group 1 at both 4 and 8 weeks after operation, comparing with the other two groups (Fig. 5B) . Histomorphometric quantification of bone tissues in both HE staining and immunohistochemical staining further confirmed the highest amount of new bone formation and Ocn-expression in Group 1, indicating the superior regenerative activity of AFSCs-premixed PRPG in alveolar defect restoration (Fig. 7) .
AFSCs alone showed a limited role in restoration of alveolar defect
By using the fibrin gel, a biological scaffold with extremely low osteoinduction property, the results of Groups 2 and 3 were further compared to reveal the effects of AFSCs on alveolar defect restoration. Although no statistically significant difference of BV/TV was observed between Groups 2 and 3 at 4 and 8 weeks after operation, a relatively higher amount of new bone formation was revealed in Group 2 than in Group 3 at 8 weeks after restoration (Fig. 5B) . Moreover, a slightly higher amount of new bone formation in Group 2 at 8 weeks after operation was further confirmed by the histomorphometric quantification of new bone area in HE staining, indicating a limited role of AFSCs alone in alveolar defect restoration (Fig. 7) .
AFSCs survived and directly participated in alveolar bone regeneration
To confirm the involvement of the implanted AFSCs in alveolar bone regeneration, histoimmunofluorescence imaging was conducted and a small amount of GFP-positive cells was detected in both Groups 1 and 2 at 4 weeks after operation. GFP-labeled cells which show green fluorescence were detected within the newly deposited bone tissue with positive Ocn-expression visible as red fluorescence, indicating that the transplanted AFSCs directly participated in alveolar bone regeneration (Fig. 8) .
Discussion
Up to date, various independent researchers have confirmed the existence and osteogenic differention potential of AFSCs in different species such as human, sheep, horse, and rat [36] [37] [38] [39] [40] . Notably, human AFSCs have been shown to display non-tumorogenicity, high proliferation rate, fetus-origin immunogenecity, and robust osteo-regenerative potential, leading to their advantage for rapid in vitro expansion and robust autogenous bone tissue engineering application [11, [40] [41] [42] [43] [44] . In facing of the mounting clinical demand and suboptimal techniques on alveolar cleft restoration, AFSCs may be particularly useful for autologous bone tissue engineering of newborns and children patients. Our general concept of AFSCs-based bone tissue engineering strategy for alveolar cleft restoration relies on the safety of amniocentesis for amniotic fluid harvest and the promising perspectives of AFSCs banking for autologous application in pediatric bone tissue engineering [19, 45] . Partially in accordance to our hypothesis, Caterina et al. [46] recently reviewed the current knowledge on bone regeneration potential of AFSCs and proposed the autologous application of AFSCs for the treatment of congenital malformations and bone defects. Hence, the affected children could benefit from their own banked, expanded and properly engineered AFSCs in the childhood. In accordance with the previous reports, we successfully isolated the rat AFSCs which showed typical fibroblastoid morphology and stable proliferation activities with no significant variation during passaging. Flow-cytometry analysis demonstrated that the cells were positive for CD29, CD44, and CD90, while negative for hematopoietic markers such as CD34 and CD45. Further investigation using biochemical staining and real-time PCR confirmed the in vitro multi-differentiation potential of rat AFSCs. Expression levels of osteogenic, chondrogenic, and adipogenic-specific genes such as Runx2, ColIa1, Ocn, Sox9, ColIIa1, and Ppar-γ were all upregulated in these cells after osteogenic, chondrogenic, and adipogenic induction, respectively. Notably, the expression level of Runx2 was only signifcantly up-regulated at 7 days after osteogenic induction, which may be due to the fact that Runx2 has been shown as an early key transcription factor for initiating osteogenesis and downstream osteogenic-specific gene expression cascade onset [47] [48] [49] . The spatiotemporal expression feature of Runx2 indicated a dynamic osteogenic differentiation process of AFSCs [50] . Moreover, the adipogenic potential of AFSCs has been reported to be relatively limited comparing with BMSCs according to some comparative and phenotype studies [51] [52] [53] [54] . While other studies showed that AFSCs have superior capacity to differentiate into many cell types. One plausible explanation for the discrepency is the different dynamic microenvironments or the stem cell origin may play an important role in modulating the behavior of each cell source [55, 56] . This is further supported by the fact that adipocytes resident in adult human bone marrow but not amniotic fluid and that BMSCs contribute to increased adipogenesis in the bone marrow correlated with age. Alternatively, it may be due to the different responsiveness of AFSCs toward the adipogenic induction. Thus further comparative genomic or proteomic approaches are needed to assess the susceptibility of AFSCs toward adipogenesis.
To evaluate the regenerative properties and application feasibility of a AFSCs-PRPG in restoration of alveolar cleft, a modified SD rat alveolar bone defect model was used in this preliminary study. AFSCs-premixed fibrin gel, AFSCs-PRPG, and fibrin gel alone were used to restore the bone defect. Our results demonstrated that the implanted AFSCs can survive in the defect site and directly participate in the bone tissue regeneration. Notably, the bone regeneration process was significantly accelerated and enhanced in AFSCs- premixed PRPG group at both 4 and 8 weeks after operation comparing with the other two groups, indicating the superior regenerative activity of the AFSCs-PRPG in alveolar defect restoration. Now, PRP is increasingly used in peridontal tissue regeneration, tooth extraction preservation and shows good results in both experimental and clinical studies without adding any stem cells [26, [57] [58] [59] . The beneficial outcomes of applying PRP, including reduction of bleeding and rapid healing, holds great promise for dental clinic procedures. However, there has been no successful report on the application of PRP gel alone for restoration of alveolar cleft or large alveolar bone defect. Alternatively, a stem cell-based tissue engineering was proposed for such conditions. According to experimental and clinical studies, it is widely accepted that stem cells-loaded PRP gel can be directly used to restore various bone and cartilage defect without setting a PRP control group, especially in the restoration of large alveolar defect [3, 4, 27, [60] [61] [62] [63] [64] [65] [66] [67] . The seemingly contradictory results, supporting both application of PRP or stem cells-loaded PRP, may be defect-model-specific, making it very hard to conclude that stem cell-loaded PRP is better than PRP alone. Moreover, it is widely accepted that there is a positive, synergistic effect of PRP on regenerative performance of pre-loaded stem cells. The positive effect of PRP could be attributed to the angiogenetic, proliferative, and differentiating effects of the TGF-β, IGF-I, and platelet-derived growth factor contained in PRP [4, 27, [59] [60] [61] [62] [63] [65] [66] [67] . The most improved results observed with the AFSCs-premixed PRPG group in our study may in fact be due to the synergistic bone forming effect of AFSCs and PRP, which served as a cytokine cocktail and a celldelivery carrier.
Moreover, although fibrin gel has been widely accepted as a celldelivery and wound-healing agent, most studies have not shown the direct osteoinductive property of fibrin glue in vivo [68] [69] [70] [71] . The results of Groups 2 and 3 further revealed the effects of AFSCs alone on alveolar defect restoration. Notably, although no statistically significant difference of BV/TV was observed between Groups 2 and 3 at 4 and 8 weeks after operation, a relatively higher amount of new bone formation was revealed in Group 2 than in Group 3 at 8 weeks after restoration. The slightly higher amount of new bone formation in Group 2 at 8 weeks after operation was further confirmed by the histomorphometric quantification of new bone area in HE staining, thus showing a limited role of the implanted AFSCs alone in alveolar restoration. Interestingly, the recent study by Mirabella et al. [72] showed that undifferentiated AFSCs do not contribute to the deposition of new bone, but exert a paracrine effect in the remodeling process, driving vascularization of the bone environment. Rodrigues et al. [73] further pointed out the concept that specific environment can pre-commit AFSCs toward an osteogenic phenotype, and that AFSCs differentiation stage has a significant impact on the outcome of the in vivo healing of large bone defects.
Overall, although the applications of AFSCs in the field of maxillofacial bone defect are very limited, our results indicate the proper regenerative performance and further application potential of the AFSCs-PRPG in the restoration of alveolar cleft. Further studies using proper biomaterial and larger animal alveolar defect model with more accurate group settings are thus urgently needed to assess the regenerative properties of AFSCs before clinical feasibility of AFSCs-based alveolar bone tissue engineering can be determined.
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